- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06493084
건강한 피험자와 과체중 비만이 있는 피험자에서 LAE102를 평가합니다.
건강한 피험자 및 과체중/비만 피험자를 대상으로 LAE102의 안전성, 내약성 및 약동학을 평가하기 위한 무작위, 이중 맹검, 위약 대조, 단일 및 다중 용량 증량 제1상 연구
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.
연구 개요
상태
상세 설명
Part A is a randomized, double-blinded, placebo-controlled, single ascending dose by Intravenous (IV) administration in 40 Healthy participants;
Part B is a randomized, double-blinded, placebo-controlled, single ascending dose by subcutaneous (SC) administration in 24 Healthy participants;
Part C is a randomized, double-blind, placebo-controlled, multiple dose ascending and expanding by subcutaneous (SC) administration in 60 overweight/obese participants.
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 201203
- Fudan Zhongshan Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female and aged 18 to 65 years (inclusive) at the screening visit
- Male Body weight ≥ 50 kg, female Body weight ≥ 45 kg. For Part A&B, 18.5 ≤ BMI ≤ 28 kg/m². For part C, 26.0 ≤ BMI ≤ 40.0 kg/m²
- Negative for human immunodeficiency virus antibody (HIV-Ab).
- Female subjects with no childbearing potential or with childbearing potential which serum human chorionic gonadotropin (hCG) test must <5mIU/mL .
- Male subjects are not allowed to donate sperm during this trial.
- Voluntarily participate in the study and provide a signed and dated informed consent form.
- Willing to comply with the scheduled visits, study treatment, laboratory tests, and other study-related procedures and requirements as stipulated in the study protocol.
Exclusion Criteria:
- With clinically significant abnormalities in vital signs, physical examination, ECG or laboratory test results specified in the protocol.
- Allergy to the investigational drug or its excipients, or a history of severe allergy (including any food or drug allergies).
- Self-reported weight change is more than 5% in the previous 3 months prior to screening.
- Diagnosed with secondary overweight or obesity.
- Any clinically significant medical conditions and any diseases affecting the safety of the subject or the determination of study results.
- History of major diseases or physical conditions in the central nervous system, respiratory system, cardiovascular system, digestive system, blood system, endocrine system, musculoskeletal diseases, mental illness, urinary system, or tumors, or any existing acute diseases, or other diseases or physical conditions that may affect the study or pose an unacceptable risk to the subjects.
- Positive for hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or syphilis spirochete antibody (TP-Ab).
- Known or suspected history of substance abuse or positive drug screening test.
- Alcohol abuse within 1 year before screening or positive alcohol breath test at baseline.
- Smoking more than 5 cigarettes per day within 3 months before screening, or unable to comply with the prohibition of smoking during the study period.
- Received any vaccine within 30 days prior to screening, or planned to receive any vaccine during the study period.
- Inability to ensure no use of any drugs, including prescription and non-prescription drugs (excluding paracetamol, ibuprofen, and topically applied eye/nasal drops and ointments with no systemic exposure risk), vitamins, supplements and herbal medicines, from 14 days before the initial administration (if the half-life of the drug used exceeds 14 days, then 5 half-lives shall apply) until the last visit period.
- Participated in any clinical trial and received an investigational medicine or medical device within 3 months prior to dosing of the investigational product.
- Underwent major surgery within 30 days before the initial administration or planned to undergo major surgery during the study period.
- Donated blood or experienced blood loss ≥400 mL within 3 months before screening or received a blood transfusion.
- Have special dietary requirements and cannot comply with a standardized diet.
- History of fainting or syncope.
- Dieting or receiving weight loss treatment within 30 days before the initial administration or experiencing major changes in lifestyle.
- Use of GLP-1 receptor agonists, or weight loss medications or systemic corticosteroids (oral or intravenous for more than 7 days), or psychiatric medications within 3 months prior to the initial administration. Applicable to part C.
- Regular engaged in muscle strength related exercise, applicable to part C.
- Other situation that the investigator considers not appropriate.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part A LAE102 IV
Single dose LAE102 by IV administration |
A single dose of LAE102 administered intravenously
다른 이름들:
|
|
위약 비교기: Part A placebo IV
Single dose placebo by IV administration |
A single dose of placebo administered intravenously
다른 이름들:
|
|
실험적: Part B LAE102 SC
Single dose LAE102 by SC administration |
Single dose of LAE102 administered subcutaneously
다른 이름들:
|
|
위약 비교기: Part B placebo SC
Single dose placebo by SC administration |
single dose of placebo administered subcutaneously
다른 이름들:
|
|
실험적: Part C LAE102 SC
Multiple dose LAE102 by SC administration |
Multiple dose of LAE102 administered subcutaneously
다른 이름들:
|
|
위약 비교기: Part C placebo SC
Multiple dose placebo by SC administration |
Multiple dose of placebo administered subcutaneously
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number & severity of participants with treatment-related adverse events as assessed by CTCAE V5.0
기간: From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part
|
Findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0 |
From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
characterize the peak of serum concentration (Cmax) of LAE102 injection in healthy subjects
기간: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
For both intravenously guttae & subcutaneous injection, to evaluate the maximum observed serum concentration(Cmax) |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
characterize the area under the serum concentration versus time curve (AUC) of LAE102 injection in healthy subjects
기간: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
For both intravenously guttae & subcutaneous injection, to evaluate the area under the serum concentration versus time curve (AUC) |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
evaluate the expression levels of Activin A in blood samples
기간: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
The validated methodology was employed to assay serum levels of Activin A in biological samples. |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
Incidence of positive Anti-drug antibody(ADA) after administration
기간: pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
Test ADA status in biological sample via validated methodology |
pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Preliminary pharmacodynamic of total body weight for multiple dose part
기간: From pre-dose to Day 168.
|
Changes and percentage changes in total body weight (kg) after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of lean mass for multiple dose part
기간: From pre-dose to Day 168.
|
Changes and percentage changes in lean mass after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of fat mass for multiple dose part
기간: From pre-dose to Day 168.
|
Changes and percentage changes in fat mass after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of thigh muscle volume for multiple dose part
기간: From pre-dose to Day 168
|
Changes and percentage changes in thigh muscle volume after administration |
From pre-dose to Day 168
|
|
Preliminary pharmacodynamic of bone mineral density(BMD) for multiple dose part
기간: From pre-dose to Day 168
|
Changes and percentage changes in BMD after administration |
From pre-dose to Day 168
|
|
BMI/waist circumference change and percentage.
기간: From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.
|
Assess the Body Mass Index (BMI)/waist circumference change and percentage. |
From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Xuening Li, Professor, Zhongshan hospital affiliated to Fundan University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- LAE102CN1001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .